# V1 Empirics Check — openai/gpt-5.4 (Variant C)

**Model:** openai/gpt-5.4
**Variant:** C
**Date:** 2026-03-25T15:43:44.595366

---

## 1. **Idea Fidelity**

The paper broadly pursues the original idea in the manifest: it uses DGCP administrative data, exploits the post-August 2020 enforcement surge in the MIPYME mandate, and asks whether stronger compliance expanded small-firm access or simply relabeled incumbent suppliers. The central empirical object—cross-agency variation in the increase in MIPYME-directed procurement—and the main outcomes on supplier participation are faithful to the proposed design.

That said, there are a few departures that matter. First, the manifest emphasized a sample of higher-volume agencies (181 with 200+ processes in both periods), while the paper shifts to 256 agencies with a looser “4 quarters in both periods” rule; that is not necessarily wrong, but it changes the identifying sample and should be justified. Second, the manifest proposed using firm creation dates to distinguish true entry from relabeling, but the paper’s decomposition mainly distinguishes prior winners from non-prior winners and current certification status; that is weaker than showing that post-2020 “new MIPYME” winners are genuinely young firms rather than old firms newly entering procurement. Third, the original framing leaned on a generalized DiD with intensity, but the paper’s treatment is a post hoc realized change in compliance over the full post-period, which raises sharper endogeneity concerns than the paper acknowledges.

## 2. **Summary**

This paper studies whether enforcement of a dormant 20 percent SME procurement set-aside in the Dominican Republic expanded supplier access. Using agency-quarter data and a continuous-treatment DiD, it finds that agencies with larger increases in MIPYME-directed procurement had fewer unique suppliers, while the share of MIPYME-certified winners rose substantially; the paper interprets this as evidence that enforcement induced relabeling of incumbents rather than genuine entry.

The question is important, the setting is interesting, and the descriptive patterns are suggestive. But the current causal design is not yet convincing enough for AER: Insights, mainly because treatment intensity is itself an outcome of post-2020 agency behavior and likely correlated with contemporaneous changes in procurement composition and supplier markets.

## 3. **Essential Points**

**1. The identification strategy is too endogenous in its current form.**  
The treatment variable is the agency-specific change in MIPYME share measured using the entire post-period, then interacted with a post dummy. This is problematic. Agencies that moved more into MIPYME-directed procurement may also be agencies that simultaneously changed contract size, procurement modality, lotting, centralization, or sectoral purchasing needs in ways that directly affect the number of winning suppliers. In other words, the paper uses a realized post-treatment choice as if it were quasi-random exposure. Agency and time fixed effects do not solve that. You need a design closer to an event-study with agency-specific adoption/intensity paths measured quarter by quarter, or at minimum a shift-share style “predicted exposure” based on pre-2020 procurement characteristics interacted with the national enforcement shock. As written, the parallel-trends tests are not enough to rescue the design.

**2. The main result may be mechanical rather than economically meaningful.**  
A set-aside can reduce the number of unique suppliers per agency-quarter simply by consolidating awards into a restricted eligibility pool or by changing the number and size of procurement processes. The paper does not show whether this reflects fewer total contracts, fewer lots, larger average contracts, or procurement moving toward modalities with fewer winners. Without conditioning on procurement volume and composition, the “fewer suppliers” result is hard to interpret as reduced access. It may just be a compositional consequence of agencies reorganizing purchases under compliance pressure. You need to show what happens to number of processes, awards, total value, average lot size, modality mix, and supplier counts within narrow process types.

**3. The relabeling mechanism is under-identified.**  
The decomposition is descriptive and currently too loose to support the paper’s headline claim. “Relabeled” suppliers are defined as firms that won before 2020 and are now MIPYME-certified, but the paper does not establish when certification occurred, whether certification was newly obtained after the enforcement shock, or whether those firms were already small before 2020. Nor does it use firm creation dates in a serious way. If the central contribution is “relabeling illusion,” you need stronger evidence: certification timing, firm age, prior procurement history, and ideally event-time changes in win rates around certification.

## 4. **Suggestions**

This paper is promising, and I think it can become substantially stronger with a more disciplined econometric design and sharper mechanism evidence.

First, I would rethink the treatment definition. The current specification,
\[
Y_{at}=\alpha_a+\gamma_t+\beta(\Delta \text{MIPYME}_a\times Post_t)+\varepsilon_{at},
\]
is essentially a two-period exposure design with treatment intensity built from realized post outcomes. That makes the coefficient difficult to interpret causally. A better approach would be to define treatment at the agency-quarter level as the contemporaneous MIPYME-directed share, instrumented if possible by predetermined exposure. For example, if some agencies had pre-2020 procurement baskets that were more amenable to set-asides—small-value goods purchases versus specialized works—you could interact those pre-period shares with the post-2020 enforcement period to obtain a predicted intensity. Even if an instrument is too ambitious, a dynamic specification using quarterly intensity rather than a single post-period average would at least reduce the “bad control / realized treatment” problem.

Second, I strongly recommend adding much richer controls for procurement composition. The paper needs a table showing whether higher-compliance agencies also changed:
- number of processes,
- number of awards,
- total contract value,
- average and median award value,
- procurement modality shares,
- object type shares (goods/services/works),
- use of direct purchase or below-threshold procedures,
- awards per process and processes per quarter.

If the supplier count falls because agencies bundle purchases into fewer, larger awards, that is a different result from incumbents crowding out entrants. Right now the paper moves too quickly from “fewer suppliers” to “reduced market access.”

Third, the magnitudes need to be presented more carefully. The coefficient of -0.63 in log suppliers sounds large until one realizes it is per unit increase in treatment intensity, where treatment ranges roughly from -0.12 to 0.71 and has mean about 0.11. The implied effect for the average agency is about 6–7 percent, and for a one-standard-deviation increase about 9 percent. Those are plausible magnitudes, but the paper should foreground them in the tables, not bury them in text. At present the raw coefficient looks much larger than the economically relevant treatment variation warrants. A concise “effect at mean treatment” and “effect at +1 SD” panel would help readers assess plausibility.

Fourth, standard errors clustered at the agency level are probably acceptable with 256 clusters, but I would still want reassurance. Because treatment varies only at the agency level and is interacted with a common post shock, inference can be sensitive to serial correlation and leverage. Please report wild-cluster bootstrap p-values for the main outcome, and perhaps randomization-inference style placebo reallocations of treatment intensity across agencies within broad sectors. Given that the baseline estimate is only marginally significant at conventional levels, the paper should not lean heavily on asterisks without these checks.

Fifth, I would push much harder on the event-study. The current pre-trend test is underpowered, and the pre-period coefficients are not especially reassuring: they are fairly large and imprecise. “Cannot reject” is not the same as “parallel.” Show confidence intervals visually; bin pre-period years if needed; and report whether high-intensity agencies differ in pre-2020 trends in procurement volume, modality mix, and average contract size, not just in supplier counts. If these agencies were already changing how they bought before 2020, the design weakens considerably.

Sixth, the mechanism section should use the supplier registry more fully. The paper says firm creation date is essential, but then does little with it. That is a missed opportunity. At minimum, classify post-2020 winning firms by:
- firm age at first win,
- whether they were registered before 2020,
- whether they first appear in the supplier registry before or after 2020,
- whether MIPYME certification appears to be newly obtained post-2020,
- prior winning history.

Then ask: did high-compliance agencies increase wins by young firms, newly registered firms, or first-time procurement participants? If not, that is much more compelling evidence of relabeling than the current decomposition.

Seventh, consider moving to supplier-agency or supplier-quarter outcomes. The current agency-quarter aggregation is coarse. If relabeling is the mechanism, you should see incumbent suppliers in high-intensity agencies disproportionately increasing their probability of winning after they become certified. A micro-level design—supplier-by-agency panel or winner-level panel—would allow more informative tests than aggregate counts alone. Even a simpler hazard-style analysis of first procurement win by supplier type would help.

Eighth, the paper should be more careful in its language. “Relabeling illusion” is catchy, but the evidence currently supports a more modest claim: stronger compliance is associated with a higher share of certified winners and no increase in entry, alongside fewer unique winning suppliers. That is not yet enough to conclude strategic relabeling by well-connected incumbents. You need to tone down the rhetoric unless you can document certification timing and incumbent advantage more directly.

Ninth, I would like to see the analysis repeated in more comparable subsamples. The heterogeneity by agency size is useful, but not enough. Hospitals, utilities, ministries, municipalities, and security agencies are very different procurement environments. Re-estimate within broad agency classes or include sector-by-quarter fixed effects. The current design risks comparing agencies with very different underlying procurement technologies.

Tenth, the paper should address sample selection more transparently. Why 256 agencies here versus 181 in the original high-volume sample? Are results stronger or weaker in the stricter sample? A table comparing estimates across alternative inclusion rules would help. Since treatment intensity is likely measured with error in small agencies, the high-volume sample may be more credible.

Finally, the paper would benefit from one or two clearer welfare-oriented outcomes. AER: Insights will want to know whether this matters economically beyond the supplier count. Did prices rise? Did contract concentration increase materially? Did small contracts become more accessible while large ones did not? Even if price data are imperfect, contract value distribution and concentration can go further. Right now the paper has an interesting negative result, but the economic significance is still somewhat thin.

Overall, I like the question and the data, and I think the descriptive fact pattern may be real. But the paper in its current form overstates what the design can identify. Tighten the treatment construction, show that the main effect is not just procurement reorganization, and provide direct evidence on certification timing and firm age. If you do that, the paper will be much more persuasive and much more useful.
